|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial显示文摘 | Florian Lordick Yoon-Koo Kang Hyun-Cheol Chung Pamela Salman Sang Cheul Oh Gy?rgy Bodoky Galina Kurteva Constantin Volovat Vladimir M Moiseyenko Vera Gorbunova Joon Oh Park Akira Sawaki Ilhan Celik Heiko G?tte Helena Melezínková Markus Moehler | 2013 | Lancet Oncology2013，，6： | 14 |
| 2 | Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?显示文摘AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3,PDGFRα/b and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition,IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%),VEGFR2 (80%),VEGFR3 (67%),PDGFRα (82%) and PDGFRβ(82%) expression,whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα revealed a predominantly cytoplasmatic staining in tumor cells,accompanied by an additional nuclear staining for VEGFR3 ,EGFR1 was almost exclusively detected on the membrane of tumor cells. PDGFRβ was restricted to stromal pericytes,which also depicted a PDGFRα expression.receptor-tyrosine-kinases coexpression in gastric adenocarcinoma and might therefore encourage an application of multiple-target RTK-inhibitors within a combination therapy. | Daniel Drescher Markus Moehler Ines Gockel Kirsten Frerichs Annett Müller Friedrich Dünschede Thomas Borschitz Stefan Biesterfeld Martin Holtmann Thomas Wehler Andreas Teufel Kerstin Herzer Thomas Fischer Martin R Berger Theodor Junginger Peter R Galle Carl C Schimanski | 2007 | World Journal of Gastroenterology2007，13，26： | 4 |
| 3 | New chemotherapeutic strategies in eolorectal caneer显示文摘 | Moehler M Teufel A Galle PR | 2005 | Recent Results Cancer Res2005，165，： | 1 |
| 4 | Involvement of alpha 1-2- fucosyltransferase I ( FUT1 ) and surface-expressed Lewis ( y ) (CD174) in first endothelial cell-cell contacts during angiogenesis 显示文摘 | Moehler TM Sauer S Witzel M | 2008 | J Cell Physiol2008，215，1： | 1 |
| 5 | Prospective,open,multi-centre phase Vll trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction显示文摘 | Moehler M Gockel I Roessler HP | 2013 | BMC Cancer2013，11，13： | 1 |
| 6 | An open-label, multicen-tre biomarker-oriented AIO phase II trial of sunitinib for patientswith chemo-refractory advanced gastric cancer 显示文摘 | Moehler M Mueller A Hartmann JT | 2011 | Eur J Cancer2011，47，10： | 1 |
| 7 | Novel ways to sensitise gastrointestinal cancer to apopsis显示文摘 | Schulze-Bergkamen H Weinmann A Moehler M | 2009 | Gut2009，58，： | 1 |
| 8 | Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer:a prospective multi-center biomarker-oriented phase Ⅱ study显示文摘 | Moehler M Mueller A Trarbach T Lordick F Seufferlein T Kubicka S | 2011 | Ann Oncol2011，22，： | 1 |
| 9 | An open-label,multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer显示文摘 | Moehler M Mueller A Hartmann JT | 2011 | Eur J Cancer2011，47，10： | 1 |
| 10 | New chemotherapeutic strategies in colorectal cancer显示文摘 | Moehler M Teufel A Galle PR | 2005 | Recent Results Cancer Res2005，165，： | 1 |
| 11 | Cetuximab with irinote- can, folinic acid and 5-fluorouracil as first-line treatment in ad- vanced gastroesophageal cancer: a prospective multi-center bin- marker- oriented phase l/study 显示文摘 | Moehler M Mueller T Trarbach T | 2011 | Ann Oncol2011，22，6： | 1 |
| 12 | Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcino-ma: two parallel, multicenter phase- 11 trials显示文摘 | Wagner AD Buechner-Steudel P Moehler M | 2009 | Br Cancer2009，101，11： | 1 |
| 13 | An open- label, multicentre biomarker- oriented AIO phase II trial of sunitinib for patients with chemo - refractory advanced gastric cancer显示文摘 | MOEHLER M MUELLER A HARTMANN JT | 2011 | Eur J Cancer2011，47，： | 1 |
| 14 | Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial显示文摘 | Ralf-Dieter Hofheinz Frederik Wenz Stefan Post Axel Matzdorff Stephan Laechelt J?rg T Hartmann Lothar Müller Hartmut Link Markus Moehler Erika Kettner Elisabeth Fritz Udo Hieber Hans Walter Lindemann Martina Grunewald Stephan Kremers Christian Constantin | 2012 | Lancet Oncology2012，，6： | 1 |
| 15 | German S3-guideline “ diagnosis and treatment of esophagogastric cancer ”显示文摘 | MOEHLER M AL-BATRAN S E ANDUS T | 2011 | Z Gastroenterol2011，49，4： | 1 |
| 16 | Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcino- ma: two parallel, muldcentre phase- Ⅱtrials显示文摘 | Wagner AD Bueclmer-Steudel P Moehler M | 2009 | BrJ Cancer2009，101，11： | 1 |
| 17 | Novel ways to sensitise gastrointestinal cancer to apoptosis 显示文摘 | Schulze-Bergkamen H Weinmann A Moehler M | 2009 | Gut2009，58，7： | 1 |
| 18 | Novel therapeutic targets in esophageal cancer: impact of chemokine receptor CXCR4显示文摘 | Gockel I Schimanski CC Moehler M | 2007 | Future Oncol2007，3，： | 1 |
| 19 | Cetuximab with irino- tecan, folinic acid and 5-fluorouracil as first-line treatment in ad- vanced gastroesophageal cancer: a prospective multi-center bio- marker-oriented phase II study 显示文摘 | Moehler M Mueller A Trarbach T | 2011 | Ann Oncol2011，22，6： | 1 |
| 20 | Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era 显示文摘 | Wagner AD Moehler M | 2009 | Curt Opin Oncol2009，21，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员